TNFRSF14: A Potential Drug Target (G8764)

Target Name: TNFRSF14

NCBI ID: G8764

TNFRSF14

TNFRSF14: A Potential Drug Target

TNFRSF14 (Leukotriene Receptor 5) is a protein that is expressed in various cell types in the body, including blood cells, epithelial cells, and smooth muscle cells. It is a member of the TNF receptor family, which is a group of cytoplasmic proteins that play a critical role in the regulation of immune and inflammatory responses.

The TNFRSF14 protein is involved in the regulation of cellular processes that are important for both the maintenance of tissue homeostasis and the regulation of inflammation. It is one of the proteins that is targeted by a drug called Ligand-Conjugated Antibodies (LCA), which are a type of monoclonal antibody that can bind to specific protein targets.

The LCA assay is a technique that is used to identify potential drug targets by using antibodies that are designed to recognize specific protein targets. The LCA assay is based on the fact that many diseases, including allergies, autoimmune diseases, and cancer, are characterized by the presence of abnormal proteins that are not properly regulated. By using antibodies that recognize specific protein targets, researchers can identify potential drug targets that can be targeted with small, Selective Insulin Growth Factor (SIGF) inhibitors.

One of the reasons why TNFRSF14 is a potential drug target is that it is involved in the regulation of cellular processes that are important for both the maintenance of tissue homeostasis and the regulation of inflammation. For example, TNFRSF14 is involved in the regulation of platelet function , which is important for the regulation of blood clotting. It is also involved in the regulation of cytokine production, which is important for the regulation of immune responses.

In addition to its role in the regulation of cellular processes, TNFRSF14 is also involved in the regulation of gene expression. Studies have shown that TNFRSF14 can interact with several transcription factors, including NF-kappa-B and STAT3, to regulate the expression of genes that are involved. in the regulation of inflammation, cell survival, and tissue homeostasis.

The use of LCA to identify potential drug targets based on the expression of specific proteins is an important tool for the development of new treatments for a variety of diseases. By using antibodies that recognize specific protein targets, researchers can identify potential drug targets that can be targeted with small, selective inhibitors. The LCA assay is a powerful tool that can be used to identify potential drug targets based on the expression of specific proteins, including TNFRSF14.

In conclusion, TNFRSF14 is a protein that is involved in the regulation of cellular processes that are important for both the maintenance of tissue homeostasis and the regulation of inflammation. It is a potential drug target that can be targeted with small, selective inhibitors using the LCA assay. Further research is needed to fully understand the role of TNFRSF14 in the regulation of cellular processes and the development of new treatments for diseases associated with its dysfunction.

Protein Name: TNF Receptor Superfamily Member 14

Functions: Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network (PubMed:9462508, PubMed:10754304, PubMed:18193050, PubMed:23761635). Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation (PubMed:19915044, PubMed:9153189, PubMed:9162022). Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions (PubMed:10754304). Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response (PubMed:23761635). In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity). Upon binding to CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with BTLA (PubMed:19915044) (By similarity). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed:19915044) (By similarity)

The "TNFRSF14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNFRSF14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets